About Us

Pamela Russell

Pamela Russell


  • Emeritus Professor, Head of Biomedical Imaging and Prostate Cancer Models, APCRC-Q
  • Emeritus Professor, IHBI, QUT
  • Adjunct Professor, Centre for Advanced Imaging, University of Queensland.

Contact Details

+61 7 3443 7240


  • DipEd, Canberra University, Australia, 1979
  • PhD, Autoimmunity, Sir Gustav Nossal, Walter & Eliza Hall Institute of Medical Research, Melbourne, 1968
  • MSc, Autoimmunity, Sir Macfarlane Burnet, Walter & Eliza Hall Institute of Medical Research, Melbourne, 1965
  • BSc, Science (Biochemistry/Microbiology) University of Melbourne, Australia, 1963


Emeritus Professor Russell, AM (PhD, Dip Ed) has built an international reputation for her work in urological cancers - in particular bladder and prostate cancers. In 2003, she was awarded Membership of the Order of Australia (AM) for her research on bladder and prostate cancer and, in 2015, she was made a fellow of the Australian Academy of Health and Medical Sciences, Limited.

Prof Russell has extensive expertise in establishing cell lines and rare xenografts from primary human tumours and generating urological cancer models, and collaborates widely, within Australia and overseas in USA and Europe. Her recent research focus has been on developing new methods for prostate specific-membrane antigen (PSMA) targeted imaging using 19F-MRI, and studying new biomarkers in exosomes, which may indicate/predict the response of CRPC to chemotherapy.

Nationally, she helped to initiate the Australian Genitourinary Oncology Group and the Prostate Cancer Foundation of Australia (PCFA) (of which she is a life member). From 2007 to 2010 Prof Russell served as an inaugural Director/Secretary of the Australasian Urological and Prostate Cancer Clinical Trials Group (ANZUP). She is also an Australian editor for Urological Research and a member of Movember’s Global Scientific Committee.

In 2006 she received a prize for outstanding research alumnus of Sydney’s Kolling Institute of Medical Research, was made a life member of the Australasian Gene Therapy Society in 2009, and in 2010, PCFA’s Prostate Cancer Researcher of the Year in Australia. She has also served on Movember’s Global Action Plan Scientific Committee (2010-14) and Research Advisory Committees.

She was Professor of Medicine, University of New South Wales (UNSW) and Director of the Oncology Research Centre at the UNSW School of Medicine at Prince of Wales Hospital, Sydney from 1992-2008.

Read More ▼

After training in immunology at the Walter & Eliza Hall Institute of Medical Research in Melbourne with Sir Macfarlane Burnet and Sir Gustav Nossal, she changed her research focus to cancer in 1984, and with Dr Derek Raghavan, set up the Urological Cancer Research Unit at Sydney University.

She has procured >$35M in grants, has published >200 peer reviewed articles, as well as several reviews and book chapters, edited one book and co-authored six patents. She is currently funded by the NHMRC and Movember GAP programs.

Prof Russell has been on peer review committees for the National Health and Medical Research Committee (NHMRC), Cancer Council Australia, Cure Cancer Australia, and regularly reviews papers from international journals. She has delivered presentations or chaired sessions at numerous international prostate cancer meetings.

She has trained 13 Honours students, 7 BSc (Med) students, 3 Masters’ students, 14 PhD and 1 MD student and 31 post-doctoral fellows.

Awards and grants


2015 Fellow of the Australian Academy of Health and Medical Science, Limited
2010 Inaugural Prostate Cancer Foundation of Australia Prize and Lecture for Outstanding Excellence
2010 Prostate Cancer Foundation of Australia's Researcher of the year
2009 Made Life Member, Australasian Gene Therapy Society
2009 Alban Gee Prize for best poster presentation at USANZ
2007 Member of the year, listed in Madison's Who's Who
2006 Made Honorary Life Member, Prostate Cancer Foundation of Australia
2006 Awarded prize for outstanding alumni of Kolling Institute of Medical Research (75th Jubilee)
2005 Listed in Marquis Who's Who in Medicine and Healthcare, USA
2003-2005 Listed in Who's Who, Australia
2003 Platinum Nomination for the CSIRO Chairman's medal.  Gene Therapy: A new approach for treating prostate cancer
2003 Order of Australia (AM) for outstanding contributions to prostate and bladder cancer research
1962 Dunlop Rubber prize for Biochemistry
1960 Commonwealth Scholarship




Translational Research Institute (TRI) Spore Grant


MicroRNA replacement therapy for indolent and aggressive prostate cancer.

Batri J, Russell PJ, Vela I, Cristina A


National Health and Medical Research Council (NHMRC)

Category 1



Immunopolymeric drugs for prostate cancer therapy

Thurecht K, Russell PJ, Mahler S, Boyd A, Howard C (AIs: Thompson L, Heathcote P, Straw R).



Category 1

APP 108043


The Microniche: A novel in-vitro and in-vivo prostate cancer model system

Doran MR, Vela I, Tse B, Russell PJ (AIs Pettit A, Wang C, Clements JA).


Australian Research Council (ARC) Linkage



Next generation hybrid nanomaterials: investigating anti-PET as a component in bispecific antibodies as a novel biomolecule couple technology

Thurecht KJ, Mahler S, Russell PJ, Walsh D, Campbell.


Prostate Cancer Foundation of Australia (PCFA) / Movember Foundation



Movember Revolutionary Team Award 3: Exploiting alterations in lipid metabolism to improve diagnosis, treatment and molecular imaging of prostate cancer.

Butler L,Collaborators: Tilley W, Hoy A, Wittert G, Nelson CC, Scott A, Swinnen J, Clayton A,Weickhardt A, Davis I, Power C, Bianco-Miotto T, Russell PJ (AI), Brooks D, Sutherland P, Parnis F


NHMRC Development Grant

Category 1



Novel prostate cancer target for diagnosis, imaging, detection of recurrence and response to therapy 

Nelson CC, Russell PJ, Walsh BJ, Campbell D.


PCFA Movember Revolutionary Team Award


Adaptive response to androgen targeted therapies: A strategic offensive on resistance

Nelson CC, et al. (AIs, include PJ Russell).


World Cancer Research (Former AICR), 103624 pounds


A humanized in vivo model to test novel therapeutic strategies against prostate cancer bone metastasis.

Hutmacher D, Denham J, Russell PJ, Williams ED, Levesque J-P, Holzapfel BA. 


ARC – Linkages, Infrastructure and Equipment Fund (LIEF)

Category 1

LEIF 50100067


The Vevo 2100 Micro-ultrasound plus LAZR Photoacoustic Imaging Platform 

Russell PJ, Gobe G, Herington A, Langton C, Thurecht K, Brereton I, Frazer I, Fielding A, Hutmacher D, Hill M


Australian Cancer Research Foundation (ACRF)

$4 million ($2.5 m obtained)

ACRF  Facility for Molecular Imaging Agents (AFMIAC)

Reutens D, Cooper MA, Smith MT, Boyd A, Richards L, Bartlett PF, Russell PJ, Walker DG, Bhalla R, Barth M, Palmeri C, Thurecht K, Venkatachalam T, Allavena R, Straw R, Tesiram Y, Bunt J, Francois M, Osborne G.


PCFA/Movember Foundation

Movember Global Action Plan Xenograft Project Grant

Williams ED, Russell PJ, Nelson C


TRI Inter-Institutional Collaborative Research Funding Award


Diagnosing small renal masses; solving the clinical problem of how best to manage patients with kidney neoplasms that are not life threatening

Gobe G, Wood S, Coward J, Russell PJ, Saunders N, Lott W (AI Hemamali Samaratunga).


Movember Xenograft project Grant


Global Action Plan-Xenografts)

Williams ED, Russell PJ, Nelson CC


Gallipoli Medical Research Foundation


 Evaluation of PSMA-based positron emission tomography and magnetic resonance imaging for detection of multiple cancer foci in localized prostate cancer patients.

Heathcote P, Thomas P, Wood S, Greenslade S, Lampe G, Shephard B, Nelson CC, Russell PJ


Australian Government Department of Health and Aging


Australian Prostate Cancer Research Centre – Queensland

Nelson CC, Clements J, Russell PJ, Herington A, Chopin L, Hutmacher D, O’Byrne K, Graves N, Yates P, Williams ED, Richard D, Wood S, Vela I, Heathcote P, Lehman M, Gogna K, McCaffrey E, Greenslade S, Lampe G, Shepherd B.


Movember Global Exosome Biomarker Project Grant


 Development of assays for the capture and detection of prostate cancer-derived exosomes and exosomal markers.

Russell PJ, Soekmadji C, Nelson CC, Hovens C.


NHMRC APP1046831

Category 1


Imaging for prostate cancer theranostics

Russell PJ, Whittaker A, Thurecht K (AIs, Nelson C, Coswin G, Heston WD, Emberton M.)






Simultaneous imaging and drug delivery for prostate cancer theranostics

Russell PJ, Whittaker A, Thurecht K, Heston WW.




Category 1


Identification of PACE-1 as a novel therapeutic target for the treatment of prostate cancer

Ling, MT, Quinn R, Russell PJ, (AI: Nelson, C)



Category 1


Comprehensive Cell Imaging Facility

Clements J, McMillan N, Whitehead JB, Beagley KW, Russell PJ, Nelson CC, Hutmacher DW, Atkinson MK, Dawson PA, Frazer IH, Gonda TJ, Hooper JD, Levesque JP J, McGuckin MA, Munster DJ, Rice AM, Thomas R, Vuckovic S, Waterhouse NJ.


ARC Discovery

Category 1



Development and validation of virtual epithelial cancer models using an integrated modelling and experimental three-dimensional approach

Hutmacher D, McElwain DL, Russell PJ, Flegg JA, Loessner D, Clements J, Dalton PD, Byrne HM.




Category 1


KLK4 is a master regulator of tumour microenvironment remodelling in prostate cancer and bone metastasis

Clements J, Nelson C, Hutmacher D, Russel PJ.


Queensland Cancer Council 614273


The role of KLK4 in prostate cancer progression

Clements JA, Hutmacher DW, Nelson CC,  Russell PJ.




Targeted nanoparticles for imaging prostate cancer

Russell PJ, Khatri A, Cowin G, Thierry B, Power C.




Application for a Syngene G:Box Chemi XT unit

Russell PJ, Nelson CC, Lin P, Clements JA, Harris J, Hooper J, Chopin L, Herington A, Stephenson SA.


Cancer Institute, NSW, Research Equipment Grant


Aperio Scan Scope Virtual Slide Scanner for collaborative cancer histopathology

Hawkins N, Ward R, Apte M,  Russell PJ, Sewell W.


NHMRC Development

Category 1



Potential therapeutic roles for a protease inhibitor

Harris J, Clements J,  Russell PJ.


Cancer Australia and PCFA (NHMRC510239)


Preclinical evaluation of novel prostate-targeted nanoparticles for imaging primary and metastatic prostate cancer

Rusell PJ, Amal R, Walsh BJ, Bucci J, de Souza P.

Changed in 2009 to : Russell PJ, Thierry B, Walsh BJ, Bucci J, de Souza P, Khatri A. $584,000


Goldstar Award, UNSW


Preclinical evaluation of novel prostate-targeted nanoparticles for imaging primary and metastatic prostate cancer

Rusell PJ, Amal R, Walsh BJ, Bucci J, de Souza P.

Awarded but not taken up as ARC Linkage successful


ARC Linkage Grants



Numerical modelling and experimental studies to design and engineer nanoparticulate systems for bioapplications

Amal R, Russell PJ, Walsh BJ, Gooding J.



Category 1


Combined novel tumour-targeted molecular and traditional chemotherapy for treating androgen refractory prostate cancer

Russell PJ.


UNSW Foundation & PCFA


Studies of bone metastasis from prostate cancer

Russell PJ, Power C.


Cancer Inst. NSW,


Establishment of networking data base and animal support for live animal imaging

Russell PJ, Khachigian L, Crowe PJ, Rae C, Wlash W, Haber M, Lock R, Yang j-lL, Tuch B, Rose M, Price W, Power C.


UNSW equipment grant


Major Research and Infra-structure equipment: Vevo and intra-vital microscopy

Khachigian L, Chesterman C, Hogg P, Jessup W, Chong B,  Kritharides L,  Gaus K, Haber M, Norris M, Kavallaris M, Lock R, Brown AJ, Gooding J, Russell PJ, Power C, Amal R, Rose M,  Geczy C, Morris M, Waite P, Ashwell K, Hill M, Carrive P,  Stoodley M, Brew B, Tuch B, Kuldip S.


UNSW, Major Research and Infrastructure


MicroCT scanner

Russell PJ, Waite P, Geczy C, Rose M, Khachigian L, Tuch B, Walsh W, Stoodley M, Yang J-L, Carrive P, Lovell N, Power C, Amal R.


Cancer Council NSW


Secreted phospholipase A2 in prostate cancer

Scott K, Graham G, Dong Q, Russell PJ.


Cancer Council NSW


Chemo-sensitising pathways in ovarian cancer

de Fazio A, Harnett P, Russell P, Associate Investigators: Bowtell D, Guminski A, Byth K, Sharma R.





Identification of novel biomarkers in tears for prostate cancer diagnosis and prognosis

Li Y, Willcox MD, Cozzi PJ, Russell PJ, Walsh BJ, Zhao Z.


Sydney Foundation of Medical Research


Studies of bony metastases

Russell PJ, Power C


UNSW Faculty of Medicine Strategic Initiatives Grant


Establishment of Biomedical Nanotechnology Centre

Kavallaris M, Davis T, Khachigian LM, Norris M, Tuch B, Russell P, Cunningham A, Bulmus V.


MSW Cancer Institute: Equipment grant


Imaging system for live small animals (Xenogen IVIS 100 System)

Russell PJ, Crowe PJ, Haber M, Khachigian L, Lock R, Ormandy C, Rose M, Bucci J, Yang J-L, Power C, Khatri A, Kavallaris M, Rawlinson W.




Inhibition of bony metastases by therapeutic agents from Novartis (alone and in combination) using prostate cancer RM-1(BM)GFP metastasis model in immunocompetent mice

Power C, Russell PJ


NSW Cancer Council


The role of the TGF-b superfamily cytokine MIC-1 in the biology of cancer

Breit S, Russell PJ


Prince of Wales Clinical School Research Enhancement Grant


The significance of mutations in the FGFR3 gene to bladder cancer progression.

Jackson P, Russell PJ, Hung T-T, Roscioli T.


Prince Henry Centenary Foundation, & Children’s Hospital


Purchase of confocal microscope

Cunningham A, Kavallaris M, Russell PJ


Prince of Wales Clinical School Research Enhancement Grant


Relationship of EGFR receptor mutation and gene variation in its signalling pathways to the synergistic effect of interferon-alpha plus erlotinib in treatment of human colon cancer cell lines.

Goldstein D, Yang J-L, Russell PJ


NSW Cancer Institute: Translational grant


Identification and validation of molecular markers of prognosis and therapeutic responsiveness in prostate cancer

Clarke S, Henshall S, Russell PJ, Horvath L, Sutherland R, Kench J, Lee C-Soon, Molloy PL, Grygiel J, Stricker P, Boyer M.


NSW Cancer Institute: Research Infrastructure grant

Infrastructure support for an established cancer genetics/genomics facility.

Hayes V, Ormandy C, Breit S, Butt A, Clark S, Daly R, Grygiel J, Henshall S, Horvath L, Kaplan W, Kench J, Kohonen-Corish M, Musgrove E, O’Brien P, Russell PJ, Sutherland R, Ward RL.


NSW Cancer Institute, Research Infrastructure grant


SESAHS Consortium for rational therapeutics

Ward R, Links M, Goldstein D, Russell PJ


Rebecca Cooper Foundation


Purchase of a tissue slicer

Katri A, Russell PJ


Department of Veterans’ Affairs Australia


Oncogenic action and therapeutic potential of PLA2 in prostate cancer.

Dong Q, Scott K, Graham G, Russell PJ


UNSW Faculty of Medicine Enhancement Grant


To purchase real time PCR.

Russell PJ, Erlich J


NHMRC Enabling Grant


Prostate Cancer Tissue Banking.

Clements JA, Risbridger, V Marshall, D Roder, J Stahl, F Gardiner, D Nicol, M Frydenberg, J Pederson, P Stricker (PJ Russell AI)


US Army Defense  Department, USA


New Investigator Award


Control of micrometastatic prostate cancer using multiple alpha targeted therapy

Li Y, Cozzi PJ, Rizvi SMA, Diwan A, Allen BJ, Russell PJ


Prince of Wales Hospital Oncology Institute Grant


Studies of gene array of p53-expressing human prostate cancer cell lines

Blair J, Russell PJ


Prince of Wales Hospital Oncology Institute Grant


Studies of chemotherapy and radiotherapy of prostate cancer

Zhang AL, Milross C, Russell PJ


Prince of Wales Hospital Oncology Institute Grant


 Top up for gene therapy work

Russell PJ, Khatri A.


Cure Cancer Foundation of Australia

$48,028 awarded but not taken up as Dr Zhao moved.

Purification, identification and functional studies of proteases expressed in prostate cancer cell lines – a functional proteomic study

Zhao J, Russell PJ


Faculty of Medicine, Enhancement grant

UNS $15,000

To purchase fluorescence microsopy imaging equipment

Russell PJ, Erhlich J.


Clive and Vera Ramaciotti


Microscopy equipment

Erlich J, Russell PJ


NHMRC equipment grant


Purchase of fluorescence microscopy imaging equipment

Russell PJ, Erlich J


Cure Cancer Foundation


Purchase of a faxitron

Broan JM, Russell PJ


National Institute of Health and National Institute of Diabetes and Digestive and Kidney Diseases Bethesda


US $216,000


The role of IL18 in the spread of prostate cancer to the bone

Russell PJ, Martiniello-Wilks R, Zhang A.


Department of Defense, US Army, Alternative Funding


US$522,000 (~A$900,000)

Formulated delivery of enzyme/pro-drug and cytokine gene therapy to promote immune reduction of treated and remote tumors in mouse models of prostate cancer.

Russell PJ, Both GW, Molloy PL and others from CSIRO


Department of Defense, US Army, New Idea Award




Studies of the role of p53 mutations in metastases of prostate cancer to bone.

Russell PJ, Brown JM


Sydney Foundation for Medical Research


Studies of prostate cancer

Russell PJ


Sydney Foundation for Medical Research


Studies of proteases in prostate cancer

Russell PJ, Zhao Z


Australian Kidney Foundation, Equipment grant


Equipment grant

Russell PJ


Clive and Vera Ramaciotti Foundation

$15,831 (equipment)

Identification of proteases associated with prostate cancer invasion and progression

Daja M, Russell PJ


FH Faulding support for CSIRO, SESAHS

And AusIndustry Start Plus, Funds for ORC, POWH: $1,220,380

Studies of gene therapy

Russell PJ and team


Sydney Foundation for Medical Research


Studies of proteases produced by prostate cancer cells, (includes equipment)

Russell PJ, Daja M


AusIndustry  grant,  for CSIRO, CSL and SESAHS


Lytic peptides for cancer therapy

CSL, CSIRO, Russell PJ teams


Australasian Urological Foundation


Cytodine methylation of regulatory sequences near glutaehione-S transferase gene in the peripheral blood of patients with prostate cancer

Russell PJ, Patel M


Leo and Jenny Leukaemia and Cancer Foundation


The role of KAI-1 in invasive bladder cancer.

Jackson P, Russell PJ




Category 1

Therapy for prostate cancer using the prostate specific membrane antigen for targeting

Russell PJ, Molloy PL, Both GW, Jackson P


NSW Cancer Council


Category 1

Gene therapy for androgen-independent prostate cancer: Preclinical Studies

Russell PJ, Molloy PL, Both GW


Sydney Foundation for Medical Research


The relationship between protease activity and onset and progression.

Russell PJ, Whittaker R.


Leo and Jenny Leukaemia and Cancer Foundation


The role of KAI-1 as an inhibitor of metastasis in human prostate cancer

Russell PJ, Glover H


Workcover NSW


Validation of a monoclonal antibody test for the early detection of bladder cancer

Russell PJ1 Kingsley E, Yu Y


NSW Cancer Council


Methylation of tumour suppressor and tumor related genes in prostate cancer.

Clark S, Molloy PL, Russell PJ



Category 1


A predictive assay for radiotherapy response in bladder cancer

Russell PJ, Braithwaite AW



Category 1


Prostate cell specific expression of a toxin gene delivered by recombinant adenovirus vectors

Russell PJ, Molloy PL, Both GW.


NSW Cancer Council

Category 1


Cellular mechanisms involved in the development of androgen-independence and metastases of prostate cancer

Russell PJ, Brown J




Low dose irradiation of human bladder tumours

Russell PJ


Leo and Jenny Cancer and Leuaemia Foundation of Australia


Improved targeting of platinum anticancer drugs in breast and genitourinary tumours

Russell PJ, Hambley T, McKeage M.


Clive and Vera Ramaciotti Foundation


Monoclonal antibodies for the treatment of bladder cancer

Russell PJ


Prince Henry Hospital Centenary Research Fund


Autocrine growth factor interactions in human bladder cancer

Russell PJ, Brown JL, Nash AR.


Department of Health


Care and maintenance of a nude mouse facility

Russell PJ, Vincent PC.




Therapeutic studies of human bladder cancer using monoclonal antibodies

Russell PJ, Garsia R, Person B, Pearce N, Raghavan D.


University of Sydney Cancer Research Fund


Nude mouse consortium: Maintenance of nude mice for use in cancer research

Russell PJ





Use of monoclonal antibodies for the diagnosis of human bladder cancer

 Russell PJ, Walker KZ, Garsia R, Raghavan D


Worksafe Australia


Screening of voided urine for occupational bladder cancer

Garsia R, Russell PJ, Kenyon R, Pearson B.


Royal Prnce Alfred Hospital Medical Fund


Cellular and Molecular studies of human bladder and prostate cancer.

Russell PJ, Raghavan D.


Leo and Jenny Leukaemia & Cancer Foundation of Australia


Analysis of expression and mutations of p53 and fms genes in urine cells of cancer patients.

Russell PJ, Grimmond S.



Category 1


Significance of abnormal expression or mutation of genes in bladder cancer

Russell PJ, Rozinova E, Grimmond S.



Category 1


Experimental studies of heterogeneity of response to chemotherapy in bladder cancer

Raghavan D, Bell D, Russell PJ, Foo T.


Australian Kidney Foundation (equipment)


Development of nude rat xenograft models for studies of intravesical therapy of human bladder cancer using radiolabelled monoclonal antibodies.

Russell PJ


Leo and Jenny Leukaemia & Cancer Foundation of Australia



Predicting response of bladder cancer to anti-cancer drugs

Russell PJ, Raghavan D.


University of Sydney Cancer Research Fund


Diagnosis and therapy of human bladder cancer monoclonal antibodies

Walker KZ, Russell PJ


University of Sydney Cancer Research Fund


Maintenance of nude mice for use in cancer research

Russell PJ, Raghavan D, Basten A, Mountford C.


University of Sydney Cancer Research Fund


Maintenance of nude mice for cancer research

Nude mouse consortium (convenor PJ Russell).


University of Sydney Cancer Research Fund


Diagnosis and management of human bladder carcinomas using murine monoclonal antibodies

Walker KZ, Russell PJ


Leo and Jenny Leukaemia & Cancer Foundation of Australia


Salary for animal house attendant

Nude mouse consortium (convenor PJ Russell).


Leo and Jenny Leukaemia & Cancer Foundation of Australia



Development of metastasis and invasion of human solid tumours

Russell PJ, Grant A



Category 1


Studies of gene expression, rearrangement and mutation in urogenital cancers.

Russell PJ, Raghavan D


NSW State Cancer Council

Category 1


Protein chemistry of phenotypic variants of prostate cancer

Raghavan D, Russell PJ


NSW State Cancer Council

Category 1



Small cell undifferentiated carcinoma of the prostate: a model of tumour heterogeneity and studies of polypeptide hormone production.

Raghavan D, Russell P, Russell PJ



Category 1


Heterogeneity and differentiation of cancers of the genitourinary tract

Raghavan D, Russell PJ, Vincent PC.


Prof Russell has procured more than $36 million in grants, has published more than 200 papers in international journals (H factor 53), and has co-authored six patents.

Research interests

prostate cancer, nanoparticles for imaging and delivery of chemotherapy, gene therapy for late stage prostate cancer, exosomes (small vesicles secreted by cancer cells), origin of cancer cells, identifying biomarkers from protein, miRNA, RNA, DNA or lipid content, animal models of prostate cancer, targeted gene therapy,chemotherapy, castrate resistant prostate cancer, and bony metastasis

Top publications

Of 220 papers, 1 book , editor of 1 book, 19 book chapters...

  • Russell PJ, Hicks JD, Burnet FM.  Cyclophosphamide treatment of kidney disease in (NZB x NZW)F1 mice.  Lancet, 1966; June 11, 287(7450):1279‑84 (Leading article). PMID: 4160875 (121 citations, Google Scholar). This paper describes the first use of cyclophosphamide for potentially treating systemic lupus erythematosus (SlE) in an animal model of disease. Cyclophosphamide is still used clinically to treat cases of SLE that are refractory to steroid therapy.
  • Russell PJ, Raghavan D, Gregory P, Philips J, Wills EJ, Jelbart M, Wass J, Zbroja R, Vincent PC.  Bladder cancer xenografts: a model of tumor cell heterogeneity.  Cancer Res, 1986; 46(4 Pt2):2035‑40. PMID: 2418959. This paper describes the establishment of a series of patient derived xenografts of human bladder cancer, shows that these are extremely heterogeneous with respect to flow cytometry, and histology, and indicates for the first time effective treatment using carboplatin, which has subsequently been adopted into the clinic.
  • Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP.  Biology and management of bladder cancer: advances and innovations.  N Eng J Med, 1990; 322(16):1129-38 Reply: N Eng J Med, 1991; 324:126. PMID: 2181313. This classic paper provided expert information about management and biology of bladder cancer.
  •  Khatri A, Husaini Y,  Ow K, Chapman J, Russell PJ. Cytosine Deaminase-Uracil Phosphoribosyl Transferase and Interleukin-12 and -18: a multimodal anticancer interface marked by specific modulation in serum cytokines. Clin Cancer Res, 2009;15(7):2323-2234.  PMID19318483. This paper shows that gene therapy and immunotherapy are synergistic against  prostate cancer.
  •  Pearce A, Simpson JD, Fletcher NL, Houston ZH, Fuchs, Whittaker AK, Russell PJ, Thurecht KJ. Localised delivery of doxorubicin to prostate cancer cells through a PSMA-targeted hyperbranched polymer theranostic.  Biomaterials, 2017;141:330-339. PMID:8711780 https://doi.org/10.1016/j.biomaterials.2017.07.004. This work uses a theranostic targeted to prostate cancer using a small molecule that binds to prostate specific membrane antigen. Both imaging and tumour regression were obtained.
More publications are available on PubMed


  • Brian Tse Postdoctoral Research Fellow, APCRC-Q


  • Dr Warick D Heston, Lerner Institute, Cleveland Clinic, USA
  • Prof Andrew Whittaker and Dr Kristofer Thurecht, Australian Institute of Biotechnology and Nanotechnology, University of Queensland
  • Dr Benjamin Thierry, Ian Wark Institute, University of South Australia
  • Dr Jonathan Harris, Institute of Health and Biomedical Innovation, QUT
  • Dr David MacFarlane, FRACP, Director, Queensland Positron Emission Tomography Service, Deputy Director, Nuclear Medicine, Royal Brisbane & Women's Hospital,  Queensland
  • Prof Andrew Boyd and Dr Jennifer Ellacott, Queensland Institute of Medical Research
  • Dr Michelle Hill, Diamantina Institute, University of Queensland

Professional memberships and associations

Membership of Professional Societies

Current Urological Society of Australasia:  Associate Member
Current Gene Therapy group now Honorary Life member, Australian Society for Gene Therapy
Current Associate member of American Association for Cancer Research
1991-2010 Member of Clinical Oncology Society of Australia
1993-2000 Founding Member, Genitourinary Cancer Urological Group
1998-1999 Vice-Chairman, Genitourinary Cancer Urological Group
1966-1995 Member of Australian Society for Immunology
1998 Executive Member, Australian Society for Gene Therapy
2007-2010 Secretary and Director, ANZUP Australian and New Zealand Prostate and Urological Cancer Clinical Trials Group Ltd


Founding member, and Director, Prostate Cancer Foundation of Australia


Peer review Committee, Prostate Cancer Foundation of Australia

2007 on

Member, Scientific Advisory Committee, ANZUP

2007 on

Member, Scientific Advisory Committee, ANZUP Prostate Cancer

Leadership in Professional Societies and Associations

1977-1978 Qualifications Committee of the Austrlaian Society of Microbiology
1979 Education Officer of the Australian society of Microbiology for ACT
1991 Member of Research Committee of COSA
1993 Founding member of Genitourinary Oncology Group GUOG
1995-1996 Secretary, GUOG
1998-1999 Vice-Chairman, GUOG
1998 Executive, Gene Therapy Group, NSW
1998-2000 Board Member, Prostate Cancer Research Foundation
2002- Member of Bioresource Committee, APCC
2004- Executive Member, APCC
2002-2004 Member of Board of Management of Biological Resources Centre (BRC), UNSW
2004-2006 Member of Advisory Committee of Biological Resources (BRAAG), UNSW
2004- Member of IP Committee, St Vincents Hospital, Sydney
2003-2006 Member of Cancer Care Committee, South Eastern Sydney Area Health Service
2005-2006 Executive member, Scientific steering Committee, Prostate Cancer Foundation of Australia
2006- Executive Member, Urological Oncology Program, NSW Cancer Institute
2007-2010 Secretary, Director, Australian Prostate and Urological Cancer Clinical Trials Group, ANZUP,